Prim S.A.
Prim, S.A. operates as a health technology, mobility, and health care products provider in Spain. The company offers collar, clavicle, armsling, hand and finger, shoulder, elbow, and wrist products. Its lower limbs products include calf brace, thigh, hip, knee, ankle, and foot related products. The company provides shoulder and back supports, bands, corsets, hyperextension braces, and thoracic pr… Read more
Prim S.A. (PRM) - Net Assets
Latest net assets as of June 2025: €132.70 Million EUR
Based on the latest financial reports, Prim S.A. (PRM) has net assets worth €132.70 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€207.94 Million) and total liabilities (€75.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €132.70 Million |
| % of Total Assets | 63.82% |
| Annual Growth Rate | 7.07% |
| 5-Year Change | 15.39% |
| 10-Year Change | 39.77% |
| Growth Volatility | 5.13 |
Prim S.A. - Net Assets Trend (2004–2024)
This chart illustrates how Prim S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prim S.A. (2004–2024)
The table below shows the annual net assets of Prim S.A. from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €128.93 Million | +2.47% |
| 2023-12-31 | €125.82 Million | +5.11% |
| 2022-12-31 | €119.71 Million | -1.45% |
| 2021-12-31 | €121.47 Million | +8.71% |
| 2020-12-31 | €111.74 Million | +0.62% |
| 2019-12-31 | €111.05 Million | +2.03% |
| 2018-12-31 | €108.84 Million | +2.61% |
| 2017-12-31 | €106.07 Million | +5.18% |
| 2016-12-31 | €100.84 Million | +9.32% |
| 2015-12-31 | €92.25 Million | -0.45% |
| 2014-12-31 | €92.66 Million | +9.33% |
| 2013-12-31 | €84.76 Million | +8.38% |
| 2012-12-31 | €78.20 Million | +8.33% |
| 2011-12-31 | €72.19 Million | +6.98% |
| 2010-12-31 | €67.48 Million | +8.45% |
| 2009-12-31 | €62.22 Million | +14.39% |
| 2008-12-31 | €54.39 Million | +11.23% |
| 2007-12-31 | €48.90 Million | +15.53% |
| 2006-12-31 | €42.32 Million | +17.90% |
| 2005-12-31 | €35.90 Million | +9.14% |
| 2004-12-31 | €32.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prim S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 130.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €10.92 Million | 8.47% |
| Common Stock | €4.26 Million | 3.30% |
| Other Comprehensive Income | €114.63 Million | 88.91% |
| Total Equity | €128.93 Million | 100.00% |
Prim S.A. Competitors by Market Cap
The table below lists competitors of Prim S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bintulu Port Holdings Bhd
KLSE:5032
|
$134.22 Million |
|
Hangzhou Flariant Co Ltd
SHG:605566
|
$134.25 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
$134.28 Million |
|
Daiken Biomedical Co., Ltd.
TW:7780
|
$134.28 Million |
|
Gansu Mogao Industrial Development Co Ltd
SHG:600543
|
$134.15 Million |
|
Capital Limited
PINK:CAPFF
|
$134.14 Million |
|
CHC Healthcare Group
TW:4164
|
$134.14 Million |
|
Saha Pathanapibul Public Company Limited
BK:SPC
|
$134.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prim S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 125,822,046 to 128,932,000, a change of 3,109,954 (2.5%).
- Net income of 10,920,000 contributed positively to equity growth.
- Dividend payments of 7,604,000 reduced retained earnings.
- Other comprehensive income increased equity by 5,986,804.
- Other factors decreased equity by 6,192,850.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €10.92 Million | +8.47% |
| Dividends Paid | €7.60 Million | -5.9% |
| Other Comprehensive Income | €5.99 Million | +4.64% |
| Other Changes | €-6.19 Million | -4.8% |
| Total Change | €- | 2.47% |
Book Value vs Market Value Analysis
This analysis compares Prim S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.20x to 1.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €3.05 | €12.80 | x |
| 2005-12-31 | €2.77 | €12.80 | x |
| 2006-12-31 | €3.26 | €12.80 | x |
| 2007-12-31 | €3.70 | €12.80 | x |
| 2008-12-31 | €3.54 | €12.80 | x |
| 2009-12-31 | €3.67 | €12.80 | x |
| 2010-12-31 | €3.97 | €12.80 | x |
| 2011-12-31 | €4.25 | €12.80 | x |
| 2012-12-31 | €4.62 | €12.80 | x |
| 2013-12-31 | €4.99 | €12.80 | x |
| 2014-12-31 | €5.42 | €12.80 | x |
| 2015-12-31 | €5.38 | €12.80 | x |
| 2016-12-31 | €6.03 | €12.80 | x |
| 2017-12-31 | €6.12 | €12.80 | x |
| 2018-12-31 | €6.28 | €12.80 | x |
| 2019-12-31 | €6.41 | €12.80 | x |
| 2020-12-31 | €6.45 | €12.80 | x |
| 2021-12-31 | €7.05 | €12.80 | x |
| 2022-12-31 | €7.02 | €12.80 | x |
| 2023-12-31 | €7.40 | €12.80 | x |
| 2024-12-31 | €7.58 | €12.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prim S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.47%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.68%
- • Asset Turnover: 1.23x
- • Equity Multiplier: 1.48x
- Recent ROE (8.47%) is below the historical average (12.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 14.42% | 7.36% | 0.98x | 2.01x | €1.45 Million |
| 2005 | 15.91% | 7.94% | 0.92x | 2.18x | €2.12 Million |
| 2006 | 17.85% | 8.34% | 1.10x | 1.95x | €3.32 Million |
| 2007 | 20.57% | 10.98% | 1.07x | 1.75x | €5.17 Million |
| 2008 | 18.21% | 10.34% | 1.02x | 1.73x | €4.47 Million |
| 2009 | 16.13% | 10.51% | 0.96x | 1.61x | €3.81 Million |
| 2010 | 12.64% | 8.97% | 0.86x | 1.64x | €1.78 Million |
| 2011 | 12.34% | 9.74% | 0.78x | 1.63x | €1.69 Million |
| 2012 | 11.68% | 10.30% | 0.85x | 1.34x | €1.31 Million |
| 2013 | 11.37% | 11.07% | 0.80x | 1.28x | €1.16 Million |
| 2014 | 10.75% | 10.57% | 0.81x | 1.26x | €695.54K |
| 2015 | 11.60% | 10.79% | 0.85x | 1.26x | €1.48 Million |
| 2016 | 12.99% | 11.90% | 0.86x | 1.27x | €3.01 Million |
| 2017 | 13.10% | 11.46% | 0.88x | 1.30x | €3.29 Million |
| 2018 | 12.97% | 10.50% | 0.97x | 1.27x | €3.24 Million |
| 2019 | 10.10% | 7.43% | 1.01x | 1.35x | €112.93K |
| 2020 | 6.19% | 4.70% | 0.90x | 1.46x | €-4.26 Million |
| 2021 | 14.34% | 10.34% | 0.94x | 1.48x | €5.28 Million |
| 2022 | 7.01% | 4.25% | 1.07x | 1.55x | €-3.58 Million |
| 2023 | 10.07% | 5.85% | 1.08x | 1.59x | €90.80K |
| 2024 | 8.47% | 4.68% | 1.23x | 1.48x | €-1.97 Million |
Industry Comparison
This section compares Prim S.A.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
No peer company data available for comparison.